Oura unveils its Ring 5 with a thinner, lighter design starting at $399

Oura launched the Ring 5 at $399, with higher-end finishes at $499, alongside a slimmer design, improved sensing, and battery life of 6 to 9 days versus 5 to 8 days for the Ring 4. The company also rolled out new software features including Blood Pressure Signals, Nighttime Breathing, live activity tracking, and on-demand care through Counsel Health, while expanding health-data imports and brain health research. The launch comes amid rising competition from subscription-free rivals, underscoring Oura’s push to defend its lead in the smart ring market.

Analysis

This is less about a single device refresh and more about Oura trying to defend the category moat before subscription-free hardware normalizes the market. The slimmer form factor matters because the prior generation’s biggest friction was not feature parity but wearability; if Oura removes the “bulk penalty,” it can keep premium pricing while expanding its addressable user base beyond quantified-self enthusiasts into mainstream jewelry-adjacent buyers. That helps the company preserve take rates on recurring subscription revenue, which is the real economic asset here, even if hardware ASPs stay high.

The second-order competitive effect is pressure on any wearable firm that relies on a bulky ring/bracelet form factor and slower software cadence. A faster release cycle plus a richer health stack increases switching costs, but also raises the execution bar: if accuracy claims don’t hold across skin tones, finger sizes, and low-motion activity, the product becomes a marketing story rather than a retention engine. The added care layer is strategically important because it shifts Oura from wellness into semi-clinical workflows, where engagement and willingness to pay can rise materially, but so can privacy and regulatory scrutiny.

The biggest medium-term risk is margin dilution from the pivot to smaller hardware and broader software entitlements. Smaller industrial design usually means higher BOM complexity, worse yield, and more engineering spend; if adoption does not accelerate enough, the gross margin profile can compress before software monetization matures. A contrarian read is that the market may be overestimating how quickly consumers will pay for add-on care and health analytics on top of an already expensive subscription, especially if rivals keep undercutting on total cost of ownership.

Key Decisions for Investors

• Short subscription-enabled wearable incumbents with weak ecosystem lock-in on any post-launch strength; if Oura’s slimmer form factor is adopted, conversion pressure should hit slower-moving competitors over the next 1-2 quarters.
• Long high-end consumer health data platform enablers on a 6-12 month view; the move toward in-app care and longitudinal health records increases demand for AI triage, remote monitoring, and privacy/security infrastructure.
• Pair trade: long premium health/wellness software, short low-differentiation hardware names in wearables. The setup favors firms with recurring revenue and clinician-adjacent workflows over pure device monetization.
• Avoid chasing the launch headline into adjacent consumer tech until shipment data and retention metrics confirm upgrade demand; the risk/reward is asymmetric only if the new form factor converts fence-sitters, not existing users.
• Watch for regulatory or privacy headlines over the next 3-6 months; if the medicalization of wellness data attracts scrutiny, that is the most likely catalyst to reverse sentiment and compress valuation multiples.